The board of directors of the Ocumension Therapeutics announced that on March 1, 2022, the Group entered into a series of cooperation arrangements with Viatris Pharmaceuticals Co., Ltd. pursuant to which the Group became the exclusive promoter to promote and market in hospitals nationwide in the People's Republic of China two ophthalmic drugs of Viatris, namely Xalatan and Xalacom, further information of which is set out below, and will charge Viatris China promotion service fees. The initial term of the promotion arrangement is from March 1, 2022 to December 31, 2026, with conditional automatic renewal. Reciprocally, Viatris China became the exclusive distributor to distribute, promote and market the Company's sodium hyaluronate eye drops in the out-of-hospital distribution and retail drug markets in the PRC, and will charge the Group relevant fees during a period.

The initial term of the distribution arrangement is from March 1, 2022 to December 31, 2026, with conditional automatic renewal. Other than the fees aforementioned, no other fees or charges will be incurred by both parties under the cooperation arrangements.